Assessment of the Interest of the Atalante Device for Patients With Manual Wheelchairs

NCT ID: NCT05909774

Last Updated: 2023-06-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-09

Study Completion Date

2017-09-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The loss of standing and walking capabilities in a paraplegic person is most often the result of damage to the spinal cord, either traumatic (accidental) or pathological and has both a somatic and a psychological impact on the quality of life, the risk of depression, and the difficulty of socio-professional reintegration in a society that is not adapted to people with disabilities.

A motorized mechanical exoskeleton is an external device intended to compensate for a muscular or neurological deficiency enabling paraplegics to stand and walk again. The Atalante exoskeleton, designed by Wandercraft company allows patients to stand upright and walk without the aid of crutches.

This early study was the first clinical investigation of the Atalante exoskeleton performed early in the development. It was used to evaluate the device design concept with respect to initial clinical safety and device functionality and guided further device modifications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this study was to test the use of the Atalante exoskeleton on 10 patients with complete motor paraplegia (ASIA A and B) with a level of injury between T6 and S1.

In this multi-centric clinical trial, patients were asked to perform between 1 and 2 days of training with Atalante exoskeleton including device training and evaluations (up to 9 hours of training and 3 hours of evaluation per patient).

The primary objective of this study was to assess patients' ability to walk straight- for 10 meters with the Atalante exoskeleton during 10-meters walk test (10MWT).

Within-group differences between the Atalante exoskeleton and the usual walking aid used by the patient in the success rate of the 10MWT were compared by a McNemar test.

The secondary objectives focused on performance evaluation with the Atalante exoskeleton. The assessments performed were:

1. Assessment of the superiority of the Atalante exoskeleton compared to the usual aid walking assistance used by the patient on the walking, verticalization (or sit-to-stand), static and dynamic balance ability
2. Assessment of the static and dynamic postural stability of the subject with the Atalante exoskeleton by observation of center of pressure displacement and velocity
3. Assessment of the perceived effort by the patient
4. Assessment of perceived safety by the patient
5. Assessment of the overall satisfaction of patients after using the exoskeleton
6. Comparison of the two types of walk on walking ability, perceived effort, and safety

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Complete Motor Paraplegia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Prospective, multicentric, comparative, randomized cross-over study
Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exoskeleton second

This group first perform tests without Atalante exoskeleton and secondly with Atalante exoskeleton. A second randomization is performed inside each group, with half of the patients first performing walk test with the "Continuous" walk and then with the "Push \& Swing" walk, and the other half doing the opposite.

Group Type EXPERIMENTAL

Test with Atalante exoskeleton in "continuous walk" type

Intervention Type DEVICE

The "continuous" walk is smoother and more physiologic than the "push and swing" walk

Exoskeleton first

This group first perform tests with Atalante exoskeleton and secondly without Atalante exoskeleton. A second randomization is performed inside each group, with half of the patients first performing walk test with the "Continuous" walk and then with the "Push \& Swing" walk, and the other half doing the opposite.

Group Type ACTIVE_COMPARATOR

Test with Atalante exoskeleton in "continuous walk" type

Intervention Type DEVICE

The "continuous" walk is smoother and more physiologic than the "push and swing" walk

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Test with Atalante exoskeleton in "continuous walk" type

The "continuous" walk is smoother and more physiologic than the "push and swing" walk

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Test with Atalante exoskeleton in "push and swing" walk type

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Under 60 years of age
* Daily and autonomous use of wheelchair
* Paraplegia with level of injury between T6 and S1
* Patient unable to walk, neither during physiotherapy session nor in a daily routine
* Patient with cognitive capacities: able to understand oral and/or written instructions, as well as instructions given by demonstration
* Able to use their upper limbs
* Can be verticalized
* Patient with a health care insurance
* Patient having given his/her written consent
* Joints amplitudes compatible with the use of the exoskeleton:
* Hip: Flexion\>115°; Extension\>15°; Abduction\>17°; Adduction \>10°; Medial rotation\>35°; Internal rotation\>10°
* Knee: Flexion\>105°; Extension\> -5°
* Ankle: Flexion\>0°; Extension\>9°; Supination\>18°; Pronation\>18°

Exclusion Criteria

* Severe or complete deficiency of the upper limbs
* Bad control of the trunk
* Vestibular disorder (loss of balance, dizziness, …) when placed in the vertical position
* Upper limbs involuntary shivers and/or movements
* Pregnant women
* A lower or upper limb amputated
* Epilepsy
* Patient carrying an active implantable medical device
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wandercraft

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thierry Albert, MD

Role: PRINCIPAL_INVESTIGATOR

COS CMPR de Bobigny

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CEREMH (Centre de ressources et d'innovation mobilité handicap)

Vélizy-Villacoublay, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2016-A01257-44

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Atalante USAbility
NCT05284708 COMPLETED NA
ExoAtlet II For SCI Patients
NCT04215081 COMPLETED NA